NCT01033721View on ClinicalTrials.gov

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Palomid 529

comparison of different dosages of drug

Trial Locations (1)

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Paloma Pharmaceuticals, Inc.

INDUSTRY